Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CPRX NASDAQ:NBIX NYSE:NVS NASDAQ:PLRX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCPRXCatalyst Pharmaceuticals$31.22+0.0%$26.42$19.05▼$32.56$3.82B0.721.72 million shs1.63 million shsNBIXNeurocrine Biosciences$153.24-0.7%$135.12$117.59▼$162.39$15.44B0.341.18 million shs510,221 shsNVSNovartis$151.07+0.4%$150.54$111.06▼$170.46$288.22B0.462.00 million shs840,895 shsPLRXPliant Therapeutics$1.21+5.5%$1.27$1.09▼$1.95$75.23M1.2678,952 shs1.52 million shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCPRXCatalyst Pharmaceuticals-0.06%+0.22%+18.85%+28.49%+26.72%NBIXNeurocrine Biosciences-1.81%-0.92%+15.84%+20.24%+25.68%NVSNovartis+0.89%+1.48%-1.06%-9.13%+35.84%PLRXPliant Therapeutics-2.54%-2.54%-13.53%-8.00%-14.81%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCPRXCatalyst Pharmaceuticals$31.22+0.0%$26.42$19.05▼$32.56$3.82B0.721.72 million shs1.63 million shsNBIXNeurocrine Biosciences$153.24-0.7%$135.12$117.59▼$162.39$15.44B0.341.18 million shs510,221 shsNVSNovartis$151.07+0.4%$150.54$111.06▼$170.46$288.22B0.462.00 million shs840,895 shsPLRXPliant Therapeutics$1.21+5.5%$1.27$1.09▼$1.95$75.23M1.2678,952 shs1.52 million shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCPRXCatalyst Pharmaceuticals-0.06%+0.22%+18.85%+28.49%+26.72%NBIXNeurocrine Biosciences-1.81%-0.92%+15.84%+20.24%+25.68%NVSNovartis+0.89%+1.48%-1.06%-9.13%+35.84%PLRXPliant Therapeutics-2.54%-2.54%-13.53%-8.00%-14.81%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCPRXCatalyst Pharmaceuticals 2.63Moderate Buy$32.173.05% UpsideNBIXNeurocrine Biosciences 2.82Moderate Buy$184.1520.17% UpsideNVSNovartis 2.31Hold$141.20-6.53% DownsidePLRXPliant Therapeutics 1.80Reduce$3.00147.32% UpsideCurrent Analyst Ratings BreakdownLatest PLRX, NVS, CPRX, and NBIX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/18/2026CPRXCatalyst Pharmaceuticals Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/8/2026CPRXCatalyst Pharmaceuticals CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Neutral$35.00 ➝ $31.505/8/2026NBIXNeurocrine Biosciences JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$177.00 ➝ $185.005/7/2026CPRXCatalyst Pharmaceuticals OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOutperform ➝ Market Perform5/7/2026CPRXCatalyst Pharmaceuticals StephensSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$32.005/7/2026CPRXCatalyst Pharmaceuticals Robert W. BairdSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/7/2026CPRXCatalyst Pharmaceuticals StephensSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOverweight ➝ Equal Weight5/7/2026NBIXNeurocrine Biosciences Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$140.00 ➝ $155.005/6/2026NBIXNeurocrine Biosciences Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetEqual Weight$185.00 ➝ $191.005/6/2026NBIXNeurocrine Biosciences CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$242.00 ➝ $246.005/6/2026NBIXNeurocrine Biosciences Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$176.00 ➝ $180.00(Data available from 5/20/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCPRXCatalyst Pharmaceuticals$596.96M6.40$2.92 per share10.69$8.27 per share3.77NBIXNeurocrine Biosciences$2.86B5.39$4.89 per share31.36$33.89 per share4.52NVSNovartis$56.58B5.10$10.88 per share13.89$20.40 per share7.41PLRXPliant Therapeutics$1.58M47.54N/AN/A$2.67 per share0.45Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCPRXCatalyst Pharmaceuticals$214.33M$1.7417.9410.130.9137.08%35.76%31.31%8/5/2026 (Estimated)NBIXNeurocrine Biosciences$478.60M$6.4923.6616.271.1821.55%19.79%13.82%7/29/2026 (Estimated)NVSNovartis$13.98B$6.9821.6415.372.6224.87%38.82%15.16%7/21/2026 (Estimated)PLRXPliant Therapeutics-$149.34M-$1.84N/AN/AN/AN/A-58.11%-44.37%8/6/2026 (Estimated)Latest PLRX, NVS, CPRX, and NBIX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/11/2026Q1 2026PLRXPliant Therapeutics-$0.36-$0.32+$0.04-$0.32N/AN/A4/27/2026Q1 2026NVSNovartis$2.11$1.99-$0.12$1.65$13.44 billion$13.52 billion3/11/2026Q4 2025PLRXPliant Therapeutics-$0.44-$0.35+$0.09-$0.38N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCPRXCatalyst PharmaceuticalsN/AN/AN/AN/AN/ANBIXNeurocrine BiosciencesN/AN/AN/AN/AN/ANVSNovartis$3.082.04%+5.28%44.13%N/APLRXPliant TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCPRXCatalyst PharmaceuticalsN/A7.106.84NBIXNeurocrine BiosciencesN/A2.932.85NVSNovartis0.960.850.65PLRXPliant TherapeuticsN/A16.8916.89Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCPRXCatalyst Pharmaceuticals79.22%NBIXNeurocrine Biosciences92.59%NVSNovartis13.12%PLRXPliant Therapeutics97.30%Insider OwnershipCompanyInsider OwnershipCPRXCatalyst Pharmaceuticals10.40%NBIXNeurocrine Biosciences4.60%NVSNovartis0.01%PLRXPliant Therapeutics6.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCPRXCatalyst Pharmaceuticals80122.38 million109.65 millionOptionableNBIXNeurocrine Biosciences2,000100.55 million95.93 millionOptionableNVSNovartis75,2671.91 billion1.91 billionOptionablePLRXPliant Therapeutics9061.92 million57.96 millionOptionablePLRX, NVS, CPRX, and NBIX HeadlinesRecent News About These CompaniesWall Street Zen Upgrades Pliant Therapeutics (NASDAQ:PLRX) to "Hold"May 19 at 1:10 AM | americanbankingnews.comPliant Therapeutics Stock Short Interest Report | NASDAQ:PLRX | BenzingaMay 17 at 11:06 PM | benzinga.comPliant Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial ResultsMay 11, 2026 | finance.yahoo.comPliant Therapeutics (NASDAQ:PLRX) Stock Rating Lowered by Wall Street ZenMay 11, 2026 | marketbeat.comPliant Therapeutics, Inc. (NASDAQ:PLRX) Receives Average Rating of "Reduce" from AnalystsMay 10, 2026 | marketbeat.comPliant Therapeutics (PLRX) Projected to Post Quarterly Earnings on MondayMay 9, 2026 | americanbankingnews.comPliant Therapeutics (PLRX) Expected to Announce Quarterly Earnings on MondayMay 6, 2026 | marketbeat.comPliant Therapeutics to Participate in the RBC Capital Markets Global Healthcare ConferenceMay 6, 2026 | globenewswire.comBML Capital Management LLC Buys Shares of 1,546,137 Pliant Therapeutics, Inc. $PLRXMay 6, 2026 | marketbeat.comPliant Therapeutics (NASDAQ:PLRX) Upgraded at Wall Street ZenMay 3, 2026 | marketbeat.comPliant Therapeutics Announces First Patient Dosed in FORTIFY, the Phase 1b Indication Expansion Trial Evaluating PLN-101095 in Patients with ICI-Refractory Solid TumorsApril 30, 2026 | markets.businessinsider.comPliant Therapeutics Announces First Patient Dosed in FORTIFY, the Phase 1b Indication Expansion Trial Evaluating PLN-101095 in Patients with ICI-Refractory Solid TumorsApril 30, 2026 | globenewswire.comWall Street Zen Downgrades Pliant Therapeutics (NASDAQ:PLRX) to SellApril 25, 2026 | marketbeat.comPliant Therapeutics Presents Promising Phase 1b Trial Data for PLN-101095 in Combination with Pembrolizumab for ICI-Refractory Advanced Tumors at AACR 2026April 18, 2026 | quiverquant.comQPliant Therapeutics Announces Presentation of Updated Data from the Phase 1 Trial of PLN-101095 in Patients with ICI-Refractory Solid Tumors at the 2026 AACR Annual MeetingApril 18, 2026 | globenewswire.comPliant Therapeutics Launches New $50 Million ATM ProgramMarch 30, 2026 | tipranks.comPliant Therapeutics (PLRX) price target decreased by 17.95% to 2.72March 27, 2026 | msn.comPliant Therapeutics Announces Upcoming Presentation of Phase 1 Clinical Trial of PLN-101095 in ...March 18, 2026 | bakersfield.comBPliant Therapeutics Announces Upcoming Presentation of Phase 1 Clinical Trial of PLN-101095 in Patients with Solid Tumors at the 2026 AACR Annual MeetingMarch 18, 2026 | globenewswire.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Pliant Therapeutics (PLRX) and Cytokinetics (CYTK)March 14, 2026 | theglobeandmail.comPliant Therapeutics, Inc.: Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2025 Financial ResultsMarch 12, 2026 | finanznachrichten.deNew MarketBeat Followers Over TimeMedia Sentiment Over TimePLRX, NVS, CPRX, and NBIX Company DescriptionsCatalyst Pharmaceuticals NASDAQ:CPRX$31.22 +0.01 (+0.02%) As of 03:20 PM Eastern This is a fair market value price provided by Massive. Learn more.Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.Neurocrine Biosciences NASDAQ:NBIX$153.24 -1.12 (-0.73%) As of 03:21 PM Eastern This is a fair market value price provided by Massive. Learn more.Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids. Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy in pediatrics and adults; NBI-921352 to treat developmental and epileptic encephalopathy syndrome in pediatrics and adults; NBI-827104 to treat epileptic encephalopathy with continuous spike-and-wave during sleep; NBI-1076986 to treat movement disorders; crinecerfront to treat congenital adrenal hyperplasia in adults and children; EFMODY to treat congenital adrenal hyperplasia and adrenal insufficiency in adults; valbenazine for the adjunctive treatment of schizophrenia; NBI-1065845 for the treatment of inadequate response to treatment in major depressive disorder; luvadaxistat to treat cognitive impairment related to schizophrenia; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; NBI-1117570 for the treatment of symptoms of psychosis and cognition in neurological and neuropsychiatric conditions; and NBI-1117569, NBI-1117567, and NBI-1065890 to treat CNS indications. The company also has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.Novartis NYSE:NVS$151.07 +0.63 (+0.42%) As of 03:21 PM Eastern This is a fair market value price provided by Massive. Learn more.Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.Pliant Therapeutics NASDAQ:PLRX$1.21 +0.06 (+5.48%) As of 03:21 PM Eastern This is a fair market value price provided by Massive. Learn more.Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Analog Devices Provides Much-Needed Pullback: How Low Can It Go? USA Rare Earth Posts Strong Q1 2026 as Massive Serra Vera Deal Looms The Great AI Rotation: Cashing In on Data Mirum Pharma: A Rare Disease Growth Story to Watch Vertical Aerospace: Pre-Flight Checks Point to a Breakout HIVE Weaponizes Power for an AI Pivot Strategy Inc. Buys Bitcoin and Eyes a Dividend Amid Market Fear Arhaus Stock Drops to 52-Week Low After Q1 Earnings Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
